The role of tumor necrosis factor antagonism in clinical practice

Journal of Rheumatology

Volumn 26, Issue SUPPL. 57, 1999, Pages 22-28

  Keystone, Edward C ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Combination therapy; Cyclosporine; Methotrexate; Rheumatoid arthritis; Sulfasalazine

Indexed keywords

CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DISEASE SEVERITY; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; PRIORITY JOURNAL; PROTEIN TARGETING; RHEUMATOID ARTHRITIS; TREATMENT PLANNING;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032897826     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. The North American Rheumatoid Arthritis Disease Management Study Group. Selection of DMARD therapy in rheumatoid arthritis [abstract]. Arthritis Rheum 1998;41 Suppl 9:S269.
2. Tugwell P, Bennett K, Gent M. Methotrexate in rheumatoid arthritis. Indications, contraindications, efficacy, and safety. Ann Intern Med 1987;107:358-66.
3. Alarcón GS, Tracy IC, Strand GM, Singh K, Macaluso M. Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients. Ann Rheum Dis 1995; 54:708-12.
4. O'Dell JR, Haire C, Erikson N, et al. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to MTX. J Rheumatol 1996;23 Suppl 44:72-4.
5. O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334:1287-91.
6. Weinblatt ME, Coblyn JS, Fraser PA, et al. Cyclosporin A treatment of refractory rheumatoid arthritis. Arthritis Rheum 1987;30:11-7.
7. Furst DE. Innovative treatment approaches for rheumatoid arthritis. Cyclosporin, leflunomide and nitrogen mustard. Baillieres Clin Rheumatol 1995;9:711-29.
8. Tugwell P, Pincus T, Yocum D, et al, for the Methotrexate-Cyclosporine Combination Study Group. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;333:137-41.
9. Stein CM, Pincus T, Yocum D, et al, for the Methotrexate-Cyclosporine Combination Study Group. Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for 48 weeks: an open-label extension study. Arthritis Rheum 1997;40:1843-51.
10. Rozman B, for the Leflunomide Investigators' Group. Clinical experience with leflunomide in rheumatoid arthritis. J Rheumatol 1998;25 Suppl 53:27-32.
11. Weinblatt ME, Kremer JM, Coblyn JS, et al. Leflunomide plus methotrexate in refractory rheumatoid arthritis [abstract]. Arthritis Rheum 1997;39 Suppl: 193.
12. Neidel J, Schulze M, Lindschau R. Association between degree of bone-erosion and synovial fluid-levels of tumor necrosis factor alpha in the knee-joints of patients with rheumatoid arthritis. Inflamm Res 1995;44:217-21.
13. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (CA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
14. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor-α (CA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.
15. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
16. Centocor, Inc., November 1998. Data on file.
17. Moreland LW. Soluble tumor necrosis factor receptor (p75) fusion protein (Enbrel) as a therapy for rheumatoid arthritis. Rheum Dis Clin North Am 1998;24:579-91.
18. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
19. Moreland LW, Baumgartner SW, Tindall EA, et al. Longterm safety and efficacy of TNF receptor (p75)-Fc fusion protein (TNFR:Fc; Enbrel™) in DMARD refractory rheumatoid arthritis [abstract]. Arthritis Rheum 1998;Suppl 44:S364.
20. Wyeth-Ayerst Laboratories, 1998. Data on file.